Prelude Therapeutics (PRLD) Corporate presentation summary

Mission and strategy

• Aims to extend precision medicine to all cancer patients, focusing on unmet needs and innovative modalities targeting oncogenic mechanisms.

• Investment thesis centers on advancing JAK2V617F mutant selective inhibitors and first-in-class KAT6A selective degraders, both targeting clinically validated pathways.

Leadership and expertise

• Leadership team includes experienced executives with backgrounds at major pharma and biotech firms.

• Board advisor Dr. Victor Sandor brings strategic and operational leadership for clinical development.

Pipeline highlights

• JAK2V617F program (PRT12396) targets myeloproliferative neoplasms (MPNs) with selective inhibition, aiming to reduce mutant allele burden and modify disease progression.

• KAT6A program (PRT13722) is a highly selective oral degrader for ER+ breast cancer, showing strong preclinical efficacy and safety, with IND filing planned for mid-2026.

• Degrader antibody conjugates (DACs) and mCALR-targeted therapies represent next-generation approaches for broader indications.